Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT03370276 2026-04-02

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 1/2 Completed

95 enrolled 15 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT04391049 2026-01-30

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Phase 1 Active not recruiting

16 enrolled 15 charts

Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

Phase NA Completed

2,054 enrolled 92 charts

Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

NCT02837042 2022-06-21

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Phase 2 Terminated

6 enrolled 10 charts

Genitourinary

Penile Neoplasms, Neoplasms, Squamous Cell

NCT01111058 2020-04-07

Everolimus Versus Placebo in Head and Neck Cancer

Phase 2 Terminated

52 enrolled 13 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01581970 2019-09-11

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Phase 2 Completed

7 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01016769 2019-06-26

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1/2 Completed

48 enrolled 15 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00661427 2018-01-11

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Completed

61 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Phase 2 Terminated

16 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT00815295 2014-12-08

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Phase 1/2 Completed

31 enrolled 11 charts

Neoplasms, Squamous Cell

NCT00485485 2012-08-07

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Completed

7 enrolled 7 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Using MC1R Genotype to Impact Melanoma Risk Behavior

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Everolimus Versus Placebo in Head and Neck Cancer

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer